Read by QxMD icon Read

Sarcomatoid Renal Cell Carcinoma

Fatemeh Yaghoubi, Maliheh Yarmohammadi, Mohammad Vasei
We report a 55-year-old man presented with anemia and weakness, history of flank pain, hematuria and nephrotic syndrome. Spiral abdominopelvic computerized tomography (CT) scan showed multiloculated cystic mass (120 ×100 ×80 mm) in lower portion of left kidney with internal enhancing solid components and coarse peripheral calcifications. Radical nephrectomy of left kidney was done and biopsy confirmed renal cell carcinoma (RCC), papillary type, sarcomatoid foci, Fuhrman grade III. We assumed that, presence of nephrotic syndrome and paraneoplastic glomerulopathy leaded to heavy proteinuria in this case...
2016: Journal of Renal Injury Prevention
Solène-Florence Kammerer-Jacquet, Laurence Crouzet, Angélique Brunot, Julien Dagher, Adélaïde Pladys, Julien Edeline, Brigitte Laguerre, Benoit Peyronnet, Romain Mathieu, Grégory Verhoest, Jean-Jacques Patard, Alexandra Lespagnol, Jean Mosser, Marc Denis, Yosra Messai, Sophie Gad-Lapiteau, Salem Chouaib, Marc-Antoine Belaud-Rotureau, Karim Bensalah, Nathalie Rioux-Leclercq
Clear cell renal cell carcinoma (ccRCC) is an aggressive tumor that is characterized in most cases by inactivation of the tumor suppressor gene VHL. The VHL/HIF/VEGF pathway thus plays a major role in angiogenesis and is currently targeted by anti-angiogenic therapy. The emergence of resistance is leading to the use of targeted immunotherapy against immune checkpoint PD1/PDL1 that restores antitumor immune response. The correlation between VHL status and PD-L1 expression has been little investigated. In this study, we retrospectively reviewed 98 consecutive cases of ccRCC and correlated PD-L1 expression by immunohistochemistry (IHC) with clinical data (up to 10-year follow-up), pathological criteria, VEGF, PAR-3, CAIX and PD-1 expressions by IHC and complete VHL status (deletion, mutation and promoter hypermethylation)...
September 13, 2016: International Journal of Cancer. Journal International du Cancer
G Simone, G Tuderti, M Ferriero, R Papalia, L Misuraca, F Minisola, M Costantini, R Mastroianni, S Sentinelli, S Guaglianone, M Gallucci
AIM: To compare the cancer specific survival (CSS) between p2-RCC and a Propensity Score Matched (PSM) cohort of cc-RCC patients. METHODS: Fifty-five (4.6%) patients with p2-RCC and 920 cc-RCC patients were identified within a prospectively maintained institutional dataset of 1205 histologically proved RCC patients treated with either RN or PN. Univariable and multivariable Cox regression analyses were used to identify predictors of CSS after surgical treatment...
November 2016: European Journal of Surgical Oncology
Tastekin Ebru, Oz Puyan Fulya, Akdere Hakan, Yurut-Caloglu Vuslat, Sut Necdet, Can Nuray, Ozyilmaz Filiz
PURPOSE: Clear cell renal cell cancers frequently harbor Von Hippel-Lindau gene mutations, leading to stabilization of the hypoxia-inducible factors (HIFs) and their target genes. In this study, we investigated the relationship between vascular endotelial growth factor (VEGF), HIF-1α, HIF-2α, p53 positivity, microvessel density, and Ki-67 rates with prognostic histopathologic factors (Fuhrman nuclear grade, stage, and sarcomatoid differentiation) and survival in clear cell renal cell carcinomas...
September 1, 2016: International Braz J Urol: Official Journal of the Brazilian Society of Urology
Dana Kivlin, Carmen Tong, Justin Friedlander, Patricia Perosio, Jay Simhan
BACKGROUND: Staghorn calculi are well-established risk factors for recurrent urinary tract infections (UTIs) and subsequent renal deterioration. Less commonly, long-term urothelial irritation from a calculus may also pose a risk of malignant transformation. CASE PRESENTATION: A 77-year-old male with multiple medical comorbidities presented with a chronic right renal pelvic staghorn calculus and findings concerning for emphysematous pyelonephritis. He was subsequently taken to the operating room for a planned laparoscopic right nephrectomy...
2016: J Endourol Case Rep
Giuseppe Simone, Gabriele Tuderti, Umberto Anceschi, Rocco Papalia, Mariaconsiglia Ferriero, Leonardo Misuraca, Francesco Minisola, Riccardo Mastroianni, Manuela Costantini, Salvatore Guaglianone, Steno Sentinelli, Michele Gallucci
PURPOSE: To compare the oncologic outcomes of partial nephrectomy (PN) and radical nephrectomy (RN) for cT1-2/N0 renal tumors and pathologically confirmed pT1-pT3a-pNx clear cell (cc)-renal cell carcinoma (RCC). Few studies compared the oncologic outcomes of PN and RN for renal tumors >7 cm. METHODS: A prospective "renal cancer" database was queried for cT<3-cN0-cM0 and pT1a-pT3a-pNx cc-RCC. Out of 1650 cases treated between 2001 and 2013, 921 were cc-RCC and 666 met inclusion criteria, 232 of which treated with minimally invasive RN and 434 with MIPN...
August 30, 2016: World Journal of Urology
Yuki Makino, Kazunari Tsuchihashi, Yosuke Shimizu, Sojun Kanamaru, Kimio Hashimoto, Noriyuki Ito
A 59-year-old man who had undergone hemodialysis for 13 years was diagnosed with left renal cell carcinoma (RCC),cT1aN0M0,in 2010. He had a laparoscopic left nephrectomy,and the pathological diagnosis at that time was clear cell carcinoma,pT1a (multifocal). At 1 year after surgery,he was diagnosed with a left renal hilar lymph node metastasis and a new right RCC,cT1aN0M0. Consequently,he underwent a right nephrectomy and retroperitoneal lymph node dissection in 2012. Pathologic diagnosis by the current classification of the right renal tumor was acquired cystic disease-associated renal cell carcinoma (ACD-associated RCC),and that of the left hilar lymph node was metastatic RCC with sarcomatoid change...
July 2016: Hinyokika Kiyo. Acta Urologica Japonica
Marc R Matrana, Ali Baiomy, Matthew Campbell, Suhail Alamri, Aditya Shetty, Purnima Teegavarapu, Sarathi Kalra, Lianchun Xiao, Bradley Atkinson, Paul Corn, Eric Jonasch, Khaled M Elsayes, Nizar M Tannir
BACKGROUND: Pazopanib is associated with increased progression-free survival (PFS) in clear-cell renal cell carcinoma (RCC) and has become a standard of care in this disease. The drug is used in metastatic non-clear-cell RCC, but data on outcomes in this setting are limited. PATIENTS AND METHODS: We conducted a retrospective data analysis of records of consecutive metastatic non-clear-cell RCC patients who received pazopanib in front-line and salvage settings between November 2009 and November 2012...
July 22, 2016: Clinical Genitourinary Cancer
Dalsan You, Chunwoo Lee, In Gab Jeong, Cheryn Song, Jae-Lyun Lee, Bumsik Hong, Jun Hyuk Hong, Hanjong Ahn, Choung-Soo Kim
PURPOSE: We evaluated the value of metastasectomy in patients treated with targeted therapy for metastatic renal cell carcinoma (mRCC). METHODS: The medical records of 325 patients who presented with mRCC were reviewed; among these patients, 33 underwent complete metastasectomy followed by targeted therapy (complete metastasectomy group), 29 underwent incomplete metastasectomy followed by targeted therapy (incomplete metastasectomy group), and 263 treated with targeted therapy alone (non-metastasectomy group)...
November 2016: Journal of Cancer Research and Clinical Oncology
Uriel Villela-Segura, Jorge García-Leiva, Perla Judith Nuñez Becerra
No abstract text is available yet for this article.
August 6, 2016: Gastroenterología y Hepatología
Kanishka Sircar, Suk-Young Yoo, Tadeusz Majewski, Khalida Wani, Lalit R Patel, Horatiu Voicu, Wandaliz Torres-Garcia, Roel G W Verhaak, Nizar Tannir, Jose A Karam, Eric Jonasch, Christopher G Wood, Pheroze Tamboli, Keith A Baggerly, Kenneth D Aldape, Bogdan Czerniak
Sarcomatoid transformation, wherein an epithelioid carcinomatous tumour component coexists with a sarcomatoid histology, is a predictor of poor prognosis in clear cell renal cell carcinoma. Our understanding of sarcomatoid change has been hindered by the lack of molecular examination. Thus, we sought to characterize molecularly the biphasic epithelioid and sarcomatoid components of sarcomatoid clear cell renal cell carcinoma and compare them to non-sarcomatoid clear cell renal cell carcinoma. We examined the transcriptome of the epithelioid and sarcomatoid components of advanced stage sarcomatoid clear cell renal cell carcinoma (n=43) and non-sarcomatoid clear cell renal cell carcinoma (n=37) from independent discovery and validation cohorts using the cDNA microarray and RNA-seq platforms...
October 2015: Journal of Pathology. Clinical Research
Sarah P Psutka, John C Cheville, Brian A Costello, Suzanne B Stewart-Merrill, Christine M Lohse, Bradley C Leibovich, Stephen A Boorjian, R Houston Thompson
OBJECTIVE: To evaluate the concordance of pathologic features in metastatic renal cell carcinoma (RCC) between the primary nephrectomy and metastasectomy specimens. METHODS: Primary nephrectomy (n = 454) and matched metastasectomy specimens (n = 680) from patients treated between 1970 and 2009 for RCC were re-reviewed by 1 urologic pathologist in a blinded fashion. RCC histologic subtype, grade, coagulative necrosis, and the presence of sarcomatoid differentiation were compared between the primary and the metastatic tumor with kappa statistics...
October 2016: Urology
Solene-Florence Kammerer-Jacquet, Angelique Brunot, Adelaide Pladys, Guillaume Bouzille, Julien Dagher, Sarah Medane, Benoit Peyronnet, Romain Mathieu, Gregory Verhoest, Karim Bensalah, Julien Edeline, Brigitte Laguerre, Alexandra Lespagnol, Jean Mosser, Frederic Dugay, Marc-Antoine Belaud-Rotureau, Nathalie Rioux-Leclercq
INTRODUCTION: Clear cell renal cell carcinomas (ccRCCs) are highly metastatic tumors with metastases detected at diagnosis (synchronous) or during follow-up (metachronous). To date, there have been no reports comparing primary ccRCC of patients with synchronous and metachronous metastases, who are different in terms of prognosis. Determining whether there is a phenotypic difference between these 2 groups could have important clinical implications. PATIENTS AND METHODS: In a retrospective consecutive cohort of 98 patients with ccRCC, 48 patients had metastases, including 28 synchronous and 20 metachronous presentations, with a follow-up of 10 years...
June 27, 2016: Clinical Genitourinary Cancer
Tao Fan, Ying-Jie Song
Pulmonary sarcomatoid carcinoma (PSC) is a rare malignant cancer composed of sarcoma and sarcoma-like elements with spindle or giant cell features. We report the case of a 60-year-old male with past medical history of right renal cell carcinoma 2 years earlier. Apulmonary nodule was detected in the left upper lobe, 23 months after nephrectomy. Systemic positron emission tomography-computerized tomography (PET-CT) revealed one high metabolic mass shadow in the left upper lobe. Chest CTscan with contrast revealed a left upper lobe mass (2...
June 2016: Journal of the College of Physicians and Surgeons—Pakistan: JCPSP
Y S Zhang, H Y Yu, F Dong, H Z Li
Objective: To explore how clinical features of renal cell carcinoma (RCC) relate to cancer patients' prognosis and survival. Methods: A total of 1 497 renal cell carcinoma patients received surgical treatments in Department of Urology, Peking Union Medical College were admitted between January 2002 and December 2012. Telephone interviews and complimentary medical records review were carried out to acquire follow-up data, including post-surgery adjuvant therapy, disease progression and survival. Results: There were 1 326 of all 1 497 RCC cases successfully followed up, including 899 male and 427 female cases...
July 1, 2016: Zhonghua Wai Ke za Zhi [Chinese Journal of Surgery]
Umberto Capitanio, Bradley C Leibovich
PURPOSE: Although the role of lymph node dissection (LND) is well defined in many urological settings, uncertainty regarding need for LND still exists for patients with renal cell carcinoma (RCC). The aim of the current review is to highlight the rationale for performing or omitting LND at the time of renal surgery. METHODS: Data were identified through a search of PubMed and Web of Science, including studies published in the last 20 years in core clinical journals...
June 30, 2016: World Journal of Urology
Christopher D Jakubowski, Emily A Vertosick, Brian R Untch, Daniel Sjoberg, Elizabeth Wei, Frank L Palmer, Snehal G Patel, Robert J Downey, Vivian E Strong, Paul Russo
BACKGROUND AND OBJECTIVES: Patients with metastatic RCC can undergo metastasectomy to improve survival time. Our goal was to provide and compare characteristics and oncological outcomes of RCC patients who underwent complete metastasectomy at a single organ site. METHODS: A total of 138 RCC patients were identified as undergoing complete metastasectomy at a single organ site including adrenal, lung, liver, pancreas, or thyroid. Competing risk regression analysis was used to assess RFS and CSS adjusting for several covariates...
September 2016: Journal of Surgical Oncology
YueJun Du, Sascha Pahernik, Boris Hadaschik, Dogu Teber, Stephan Duensing, Dirk Jäger, Markus Hohenfellner, Carsten Grüllich
OBJECTIVE: To analyze the survival and prognostic factors of patients with renal cell carcinoma (RCC) with bone metastasis (BM). METHODS AND MATERIALS: Data of all patients with RCC with BM treated between January 2006 and March 2015 were retrieved from our database and analyzed retrospectively. Overall survival (OS) from diagnosis of BM was analyzed for the whole cohort and selected subgroups. Statistical analyses of clinical and pathological variables were performed using Cox regression and the Kaplan-Meier method...
October 2016: Urologic Oncology
Yong Hyun Park, Yong-June Kim, Seok Ho Kang, Hyeon Hoe Kim, Seok-Soo Byun, Ji Youl Lee, Sung-Hoo Hong
PURPOSE: We aimed to elucidate the association between perioperative blood transfusion (PBT) and the prognosis of patients undergoing curative surgery for renal cell carcinoma (RCC). METHODS: In all, 3,832 patients with RCC who had undergone curative surgery were included in this study from a multicenter database. PBT was defined as the transfusion of packed red blood cells within seven days before surgery, during surgery, or within the postoperative hospitalization period...
2016: Journal of Cancer
H Moch
Histological tumor grading is an accepted prognostic parameter of renal cell carcinoma (RCC). In 2012, the International Society of Urologic Pathologists (ISUP) proposed a novel grading system for RCC, mainly based on the evaluation of nucleoli: grade 1 tumors have nucleoli that are inconspicuous and basophilic at ×400 magnification; grade 2 tumors have nucleoli that are clearly visible at ×400 magnification and eosinophilic; grade 3 tumors have clearly visible nucleoli at ×100 magnification; and grade 4 tumors have extreme pleomorphism or rhabdoid and/or sarcomatoid morphology...
July 2016: Der Pathologe
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"